Table 1 Demographic s and clinical characteristics of Sample
From: A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD
NS2359 | Placebo | ||
|---|---|---|---|
Subjects Randomised | 63 | 63 | |
Gender | Male | 47 (74.6%) | 42 (66.7%) |
Female | 16 (25.4%) | 21 (33.3%) | |
Age | 18–25 | 13 (20.6%) | 13 (20.6%) |
Median (Range) | 35.0 (18.8–54.1) | 35.2 (19.0–51.1) | |
Origin | Caucasian | 51 (81.0%) | 54 (85.7%) |
African American | 4 (6.3%) | 3 (4.8%) | |
Asian | 3 (4.8%) | 0 (0.0%) | |
Other | 5 (7.9%) | 6 (9.5%) | |
Previous Treatment for ADHD | Yes | 17 (27.0%) | 18 (28.6%) |
No | 46 (73.0%) | 45 (71.4%) | |
ADHD Subgroup | Inattentive | 17 (27.0%) | 29 (46.0%) |
Hyperactive/Impulsive | 0 (0.0%) | 1 (1.6%) | |
Combined | 38 (60.3%) | 32 (50.8%) | |
Not Classified | 8 (12.7%) | 1 (1.6%) | |
Weight (kg) | Median (range) | 80.3 (54.9–142.9) | 78.9 (48.5–133.4) |
Height (cm) | Median (range) | 173 (152–197) | 175 (151–188) |
Smoker | Yes | 16 (25.4%) | 15 (23.8%) |
Former | 9 (14.3%) | 17 (27.0%) | |
No | 38 (60.3%) | 31 (49.2%) | |
Alcohol | Yes, Average | 53 (84.1%) | 58 (92.1%) |
Consumption | Yes, Excessive | 0 (0.0%) | 0 (0.0%) |
No | 10 (15.9%) | 5 (7.9%) | |
Hamilton Depression score | Median (Range) | 3.0 (0.0–15.0) | 4.0 (0.0–12.0) |
CGI Severity of Illness | 4 – Moderately | 30 (47.6%) | 29 (46.0%) |
5 – Markedly | 28 (44.4%) | 31 (49.2%) | |
6 – Severely | 4 (6.3%) | 3 (4.8%) | |
7 – Extremely | 1 (1.6%) | 0 (0.0%) |